Kornimate/medical-research-clean huggingface dataset:
repetitive transcranial magnetic stimulation (rtms) for obsessive-compulsive disorder (ocd)

Conditions: Obsessive-Compulsive Disorder

Summary: the study aims to assess the impact of repetitive transcranial magnetic stimulation (rtms) on brain imaging and neurophysiological measures of cognitive control in patients with obsessive-compulsive disorder (ocd).

with a prevalence of nearly 3%, obsessive-compulsive disorder (ocd) is one of the most common psychiatric disorders in the us. the first line of treatment for ocd comprises pharmacotherapy with serotonin reuptake inhibitors (sris) and cognitive behavioral therapy (cbt). although adherence to these therapies has been shown to improve symptoms in at least half of patients, some have residual symptoms and a small percentage are refractory to standard therapies. transcranial magnetic stimulation (tms) may offer an alternate, less-invasive therapy.

Eligibility criteria:
inclusion criteria: * primary diagnosis of obsessive compulsive disorder, as confirmed by the structured clinical interview for the diagnostic and statistical manual of mental disorders, 4th edition, text revision (dsm-iv-tr) (scid). * subjects should have at least a moderate level of ocd severity as defined by a yale-brown obsessive compulsive disorder scale (ybocs) score of ≥ 20. exclusion criteria: * individuals diagnosed by the investigators with the following conditions: bipolar disorder (lifetime), any psychotic disorder (lifetime), history of substance abuse or dependence within the past year (expect nicotine and caffeine). * an axis ii personality disorder, which in the judgment of the investigator may hinder the patient in completing the procedures required by the study protocol. * individuals with a clinically defined neurological disorder including, but not limited to: stroke, tics, space occupying brain lesion, any history of seizures except those therapeutically induced by electroconvulsive therapy (ect), history of cerebrovascular accident, transient ischemic attack within two years, cerebral aneurysm, dementia, parkinson's disease, huntington chorea, multiple sclerosis. * increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure (such as after large infarctions or trauma), or history of significant head trauma with loss of consciousness for \>5 minutes. * history of treatment with rtms therapy for any disorder. * history of treatment with deep brain stimulation. * cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease. * intracranial implants (e.g. aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed. * current illicit drug use.

Keywords: ocd tms neuromodulation obsessive-compulsive disorder transcranial magnetic stimulation imaging
understanding the metabolic and functional derangement of primary mitral regurgitation: a feasibility study using carbon 11(c-11) acetate cardiac positron emission tomography magnetic resonance imaging (pet-mri)

Conditions: Mitral Valve Regurgitation

Summary: the aim of this pilot imaging study is to investigate the underlying changes in myocardial oxidative metabolism, myocardial inflammation and alterations in extracellular volume in patients with chronic compensated moderate-severe primary mitral regurgitation (pmr). the pet tracer \[11c\] acetate will be used to image and quantify myocardial oxygen consumption (mvo2) in hearts of the study participants. cardiac magnetic resonance imaging (cmr) using a gadolinium-based contrast agent (gbca) will be performed to assess for and quantify expansion of myocardial extracellular volume (ecv) and myocardial inflammation. we will enroll a total of 12 participants, nine of whom will be patients with chronic, compensated asymptomatic moderate-severe pmr evaluated at the uab cardiovascular disease and structural valve clinic and three normal control subjects.


Eligibility criteria:
inclusion criteria: * at least 18 years of age. * patients with chronic, asymptomatic, compensated pmr evaluated in the uab structural valve clinic or normal controls identified from a normal aged matched population. * negative urine or serum β-human chorionic gonadotropin (hcg) test within 48 hours of \[11c\] acetate administration in women of childbearing potential. women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing. exclusion criteria: * inability to provide informed consent * pregnancy * inability to lie still for the imaging study * weight exceeding the weight limit of the pet imaging table (500 pounds) * comorbidities including any of the following: history of coronary artery disease, prior coronary revascularization, prior myocardial infarction, prior open sternotomy, history of congestive heart failure, history of non-ischemic cardiomyopathy including dilated, restrictive, hypertrophic, amyloid heart disease, cardiac sarcoidosis, history of hypertension, diabetes mellitus, chronic kidney disease with a glomerular filtration rate (gfr) less than 60 ml/min/1.73 m2 , history of other valvular heart disease defined as mitral stenosis, aortic stenosis, more than mild aortic regurgitation, more than mild tricuspid regurgitation, history of more than mild pulmonary hypertension and history of cancer with exposure to chemotherapy or radiotherapy. * contraindication for gadolinium-based contrast agent, prohance (gadoteridol) * contraindication for mri study (e.g. non-removable metal implants or certain tattoos)
cohort study of pioglitazone and cancer incidence in participants with diabetes mellitus.

Conditions: Diabetes Mellitus, Type 2, Cancer

Summary: the purpose of this study was to evaluate whether treatment with pioglitazone is associated with risk of incident cancer at the 10 most common sites in a cohort of participants with recognized diabetes.

the study enroll a large population of approximately 252467 participants. the study would analyze association of cancer and pioglitazone in 2 cohorts based on the usage of pioglitazone. participants in were originally planned to be followed-up from january 1, 1997 to december 31, 2005. based on the discussion with advisory board, it was recommended to increase the study population and duration of follow-up. the follow-up period was extended to june 30, 2012 for the study. this multi-center trial was conducted in the united states of america. the overall time to participate in this study was approximately 15.5 years. participants were followed-up from january 1, 1997 up to june 30, 2012 for the assessment of cancer risk associated with pioglitazone use.

Eligibility criteria:
inclusion criteria: 1. has been in the kpnc diabetes registry diabetes mellitus (dm) registry, aged 40 years or older and are members of kpnc as of january 1, 1997, or 2. has been in the dm registry, reached aged 40 years between january 1, 1997 and june 30, 2005 and are kpnc members on their 40th birthday, or 3. has joined kpnc after january 1, 1997, aged 40 years or older when they are identified by the dm registry between january 1, 1997 and june 30, 2005. exclusion criteria: 1. age less than (\ =) 4 months that started in the first 4 months after entering in the cohort. 3. gap in kpnc membership \>= 4 months that started in the first 4 months after entering in the cohort. 4. participant with a diagnosis of human immunodeficiency virus (hiv). 5. participants with evidence of selected surgeries for some cancer sites. 6. all prevalent cancers at baseline, that is, all participants ever diagnosed with cancer other than non-melanoma skin cancer.

Keywords: drug therapy
a single center clinical evaluation of same sitting hybrid revascularization: robotic coronary artery bypass grafting and percutaneous coronary intervention for the treatment of coronary artery disease

Conditions: Coronary Artery Disease

Summary: the primary objective of this study is to assess the safety and effectiveness of same sitting, simultaneous hybrid robotic assisted coronary artery bypass grafting (cabg) and percutaneous coronary intervention (pci) in the treatment of obstructive multivessel coronary artery disease. a secondary objective is the assessment and standardization of optimal operator techniques and comparative study of patients undergoing cabg during study period.

the study population will consist of patients with multivessel coronary artery disease requiring cabg with suitable anatomy for combination cabg and pci of non-bypassed arteries. the primary endpoint of this feasibility study is a 30-day composite of major adverse clinical events including death, repeat revascularization, stroke and/or myocardial infarction. the secondary endpoints include: 1. successful completion of same sitting cabg and coronary stent procedure 2. successful completion of cabg and pci during single hospitalization 3. achievement of complete revascularization 4. patency of the lima and stented vessels as determined by coronary angiography at time of procedures or prior to discharge and by cardiac computed tomographic angiography (cta) or coronary angiography at 1 year. 5. stent thrombosis at 24 hours (acute), 30 days (sub acute), and 1 year (late) 6. one-year composite clinical event endpoints of major clinical events including death, repeat revascularization, myocardial infarction, and freedom from angina 7. comparative analysis of hospital, 30 day, and 1 year events of hybrid cabg patients compared to consecutive patients undergoing off pump cabg with standard thoracotomy during study period

Eligibility criteria:
inclusion criteria: * requirement for cabg * anatomy and body habitus suitable for robotic cabg * requirement of revascularization of arteries amendable for pci but not accessable by robotic cabg exclusion criteria: * need for emergent cabg

Keywords: coronary artery disease robotic coronary artery bypass surgery percutaneous coronary intervention hybrid coronary revascularization
acute effects of inspiratory muscle training at different intensities in healthy people

Conditions: Healthy

Summary: at least 30 volunteers will be included in the study. after questioning the demographic and clinical information of the participants, dyspnea perception, respiratory functions, respiratory muscle strength, heart rate variability, arterial stiffness, and blood pressure and physical activity levels will be evaluated. inspiratory muscle training will be done for 15 minutes with an electronic device. respiratory training will be applied at three different concentrations with 10%, 30% and 60% of maximal inspiratory pressure. heart rate variability, arterial stiffness, and blood pressure measurements will be repeated after inspiratory muscle training sessions at different intensities.

cardiovascular diseases are the leading cause of mortality in developed and developing countries and constitute a significant morbidity burden for life. cardiovascular diseases risk factors include obesity, lipid profile, unhealthy diet, sedentary lifestyle, high blood pressure, increased arteriosclerosis. although aerobic exercise is recommended as exercise modality to reduce cardiovascular risk, the effects of resistant exercise on cardiovascular health are not clear. in addition, regular aerobic and resistant exercise regulate cardiac autonomic function. inspiratory muscle training is a time-efficient, well-tolerated and safe approach for both healthy people and people with chronic diseases. long-term inspiratory muscle training has been shown to increase respiratory muscle strength and decrease blood pressure in healthy individuals. one-session inspiratory muscle training has been shown to improve autonomic function in smokers and older individuals. however, the effects of different intensities of inspiratory muscle training on blood pressure, autonomic function, and arterial stiffness in healthy young people are not fully understood. for these reasons, the aim of the study is to investigate the acute effects of inspiratory muscle training at different intensities in healthy people. at least 30 volunteers will be included in the study. after questioning the demographic and clinical information of the participants, dyspnea perception, respiratory functions, respiratory muscle strength, heart rate variability, arterial stiffness, and blood pressure and physical activity levels will be evaluated. inspiratory muscle training will be done for 15 minutes with an electronic device. respiratory training will be applied at three different concentrations with 10%, 30% and 60% of maximal inspiratory pressure. heart rate variability, arterial stiffness, and blood pressure measurements will be repeated after inspiratory muscle training sessions at different intensities.

Eligibility criteria:
inclusion criteria: * healthy people exclusion criteria: * body mass index (bmi) \> 30 kg/m² * smoking * the presence of exercise habit * medication use * neurological, cardiovascular or respiratory disorders
safety and efficacy study of bugusan (bgs)to treat osteoporosis.

Conditions: Osteoporosis

Summary: the objective is to evaluate the effects on biomarkers and safety of bgs in postmenopausal patients with osteoporosis.

the objective is to evaluate the effects on biomarkers and safety of bgs in postmenopausal patients with osteoporosis by a study of randomized, double blind, placebo-controlled, parallel group.

Eligibility criteria:
inclusion criteria: 1. postmenopausal women between the ages of 45 and 75 years with a natural menopause ≧ 6 months and serum e2 values \< 20 pg/ml, serum fsh values ≧ 25 miu/ml; 2. patients have bone mineral density \<-2.5 sd of t score at the lumbar spine (l2-l4); 3. all patients must sign the informed consent form (icf) prior to the trial. exclusion criteria: 1. any x-ray film that documents substantial scoliosis, or spinal secondary osteoporosis; 2. any x-ray film that documents bone fracture within 3 month prior to the trial. 3. medication such as estrogen, bisphosphonates, calcitonin, fluoride, glucocorticoids, ipriflavone intake within 3 weeks prior to the trial; 4. use of other chinese medicine within 2 weeks prior to the trial; 5. patients with significant renal function impairment (creatinine\>2mg/dl) and liver function impairment (ast and alt \> 2 x the upper limit of normal range); 6. patients have laboratory test abnormality, which in the investigator's opinion might confound the study; 7. patients have severe cardiac disease, e.g. unstable angina pectoris, myocardial infarction, congestive heart failure (new york heart association functional classification iii and iv); 8. patients have life threatening disease; 9. patients are allergic to any of the composition of chinese medicine; 10. significant concomitant disease or medical history that could interfere with the study as judged by the investigator;
genetic analysis of familial brain aneurysms

Conditions: Intracranial Aneurysm

Summary: this study will investigate cerebral (brain) aneurysms and their possible inheritance patterns in families. it will try to determine how often brain aneurysms occur in families in which more than one member has had an aneurysm and to find the gene or genes that contribute to their development. people in families in which more than one family member had a cerebral aneurysm are eligible for this 1-day study. they will undergo the following procedures: * blood will be drawn (no more than 3 to 4 tablespoons) for research to identify genes that contribute to the development of brain aneurysms. * a magnetic resonance angiograph (mra) scan will be done to examine a specific brain area where aneurysms typically occur. magnetic resonance imaging uses a strong magnetic field and radio waves to produce images of the brain and detect abnormalities. if a more detailed picture of the brain is needed than can be obtained with mra, a more specific mra scan will be done using a contrast dye to enhance the images. patients may be invited to participate in related nih research studies.

this study is designed to explore the genetics of familial cerebral aneurysms. families in which more than one person has had a known cerebral aneurysm will be studied. family histories will be obtained and participants identified who are willing to come to the nih clinical center for an mrangiograph and venipuncture. dna will be isolated and linkage studies undertaken to identify loci involved in the etiology of familial cerebral aneurysms, using standard linkage approaches.

Eligibility criteria:
inclusion criteria: participants and their relatives that are affected or at a higher risk for cerebral aneurysms will be enrolled in this protocol. exclusion criteria: for the mr angiograph portion of the study, any participant that is not able to sign the clinical center consent form due to metal implants, pregnancy, claustrophobia, or an allergy to gadolinium as a contrast will be excluded from the imaging part of the study.

Keywords: intracranial aneurysms cerebral loci susceptibility genes cerebral aneurysm familial cerebral aneurysm genetics
lid wiper epitheliopathy trial

Conditions: Lid Wiper Epitheliopathy

Summary: the purpose of this study is to evaluate the effect of contact lens lubricity on lid wiper epitheliopathy (lwe) in symptomatic contact lens wearers. lwe is defined as an alteration of that portion of the marginal conjunctival epithelium of the upper eyelid that wipes the ocular surface during blinking.

this study will be conducted in two stages. in stage 1, participants will wear either spectacles or contact lenses for two weeks to determine the impact of interruption of contact lens wear on lwe. in stage 2, a second cohort of participants will wear one of two contact lens brands for two weeks, and lwe and ocular discomfort will be compared.

Eligibility criteria:
inclusion criteria: * sign informed consent document. * severe lid wiper epitheliopathy (upper lid) in either eye. * currently wearing spherical daily disposable soft contact lenses or daily wear soft contact lenses in both eyes with at least 3 months of contact lens wearing experience. * symptomatic as determined by the speed questionnaire. * willing to follow visit schedule. * habitual contact lens power with the range of -1.00 to -6.00 diopters (d) with best corrected distance visual acuity greater than or equal to 20/25 in each eye. * astigmatism less than or equal to 0.75d. * possess spectacles which provide visual acuity of at least 20/25 in each eye. * willing and able to complete daily diaries. * other protocol-defined inclusion criteria may apply. exclusion criteria: * eye injury within 12 weeks immediately prior to enrollment. * any ocular condition that would contraindicate contact lens wear. * any use of systemic or ocular medications that would contraindicate contact lens wear, as determined by the investigator. * currently wearing toric or multifocal soft contact lenses. * participation in a clinical study (including contact lens or contact lens care product) within the previous 30 days. * routinely sleeps in lenses for at least 1 night per week. * other protocol-defined exclusion criteria may apply.

Keywords: ocular discomfort contact lenses myopia
dichoptic virtual reality therapy for amblyopia in adults

Conditions: Amblyopia; Anisometropia; Strabismus

Summary: this was a randomized, masked, controlled study of the effect of a virtual reality, binocular, 3-dimensional video game on visual acuity and stereopsis in adult patients with amblyopia. the trial has been halted as of june 2016 and will not be evaluating any new subjects for enrollment.


Eligibility criteria:
inclusion criteria: * interpupillary distance of 60-66 mm * age 15-40 * anisometropic amblyopia or strabismic amblyopia * best corrected visual acuity of 20/30 or worse in the amblyopic eye * no prior therapeutic use of the software * no other ongoing therapies including patching or recent eye muscle surgery * no vested interest in the product * ability attend visits and complete the training session, and to stop the intervention after the specified intervention period exclusion criteria: * stimulus-deprivation amblyopia. * organic lesions of the eye preventing the establishment of good vision (eg. media opacities, abnormalities in the fundus or optic nerve). * lesions of the brain preventing the establishment of good vision (eg. cortical visual impairment). * establishment of normal vision by refractive adaptation (wearing glasses after presentation). * patients diagnosed with photosensitive epilepsy. * inability to comply with the follow-up visits required. * history of pathologic nystagmus (congenital or sensory).

Keywords: amblyopia dichoptic virtual reality stereopsis stereo vision visual acuity binocular
antimicrobial prophylaxis in thyroid and parathyroid surgery

Conditions: Thyroid Disease; Parathyroid Disease

Summary: the effectiveness of antimicrobial prophylaxis (amp) for prevention of surgical site infection (ssi) following thyroid and parathyroid surgery remains uncertain. present prospective randomized control study (ito-rct1) assessed the effectiveness of amp in clean neck surgery associated with thyroid and parathyroid disease.

between november 2010 and april 2012, 2164 consecutive patients who agreed to attend the randomized control study were enrolled. all the participants received surgery for thyroid and parathyroid disease at ito hospital and randomized in three groups; group a (n=541): operation with amp (pipc, piperacillin sodium), group b (n=541): operation with amp (cez, cefazolin sodium), and group c (n=1082): operation without amp. exclusion criteria * patients who did not agree to attend the randomized control study. * patients who received the operation including mediastinum with sternotomy. * patients who received the operation including additional resection of trachea, esophagus and larynx. * patients who received the re-operation for post-operative bleedings. * patients who had known allergy to cephem or penicillin.

Eligibility criteria:
inclusion criteria: * between november 2010 and april 2012, 2164 consecutive patients who agreed to attend the randomized control study were enrolled. all the participants received surgery for thyroid and parathyroid disease at ito hospital. exclusion criteria: * patients who did not agree to attend the randomized control study. * patients who received the operation including mediastinum with sternotomy. * patients who received the operation including additional resection of trachea, esophagus and larynx. * patients who received the re-operation for post-operative bleedings. * patients who had known allergy to cephem or penicillin.

Keywords: antimicrobial prophylaxis amp surgical site infection ssi thyroid thyroidectomy parathyroid surgery